Author: Molvi, Zaki ; Dao, Tao ; Klatt, Martin G ; White, Thomas E ; Lorenz, Ivo C ; O'Reilly, Richard J ; Korontsvit, Tatyana ; Mun, Sung Soo ; Nyakatura, Elisabeth K ; Balderes, Paul J ; Pohl, Mary Ann ; Khan, Abdul G ; Scheinberg, David A

Phosphopeptides derived from dysregulated protein phosphorylation in cancer cells can be processed and presented by MHC class I and class II molecules and, therefore, represent an untapped class of tumor-specific antigens that could be used as widely expressed "public" cancer neoantigens (NeoAgs). We generated a TCR mimic (TCRm) mAb, 6B1, specific for a phosphopeptide derived from insulin receptor substrate 2 (pIRS2) presented by HLA-A*02:01. The pIRS2 epitope's presentation by HLA-A*02:01 was confirmed by mass spectrometry. The TCRm 6B1 specifically bound to pIRS2/HLA-A2 complex on tumor cell lines that expressed pIRS2 in the context of HLA-A*02:01. Bispecific mAbs engaging CD3 of T cells were able to kill tumor cell lines in a pIRS2- and HLA-A*02:01-restricted manner. Structure modeling shows a prerequisite for an arginine or lysine at the first position to bind mAb. Therefore, 6B1 could recognize phosphopeptides derived from various phosphorylated proteins with similar amino acid compositions. This raised the possibility that a TCRm specific for the pIRS2/HLA-A2 complex could target a range of phosphopeptides presented by HLA-A*02:01 in various tumor cells. This is the first TCRm mAb to our knowledge targeting a phosphopeptide/MHC class I complex; the potential of this class of agents for clinical applications warrants further investigation.

01 Jun 2021·VirologyQ3 · MEDICINE

A human bispecific neutralization antibody against four serotypes of dengue virus

Q3 · MEDICINE

Article

Author: Yu, Yunzhou ; Chen, Lei ; Lu, Jiansheng ; Wang, Rong ; Yang, Zhixin

In tropical and subtropical countries, dengue virus (DENV) infections have been increasing; however, we still lack effective therapy. In the present study, we aimed to engineer a bispecific antibody (subsequently named LUZ-8F2-6B1), based on monoclonal antibody 6B1, which has anti DENV-1, 2, and 3 activity, and 8F2, which has anti DENV-4 activity. LUZ-8F2-6B1 displayed potent neutralization activity against four serotypes of DENV by binding to the envelop protein. In vivo, we demonstrated that LUZ-8F2-6B1 could provide protection against infection by four serotypes of DENV in a mouse model. In addition, the deletion of nine amino acids in the Fc region (LUZ-8F2-6B1-9del) completely abolished the antibody-dependent enhancement observed at lower doses of the antibody. Thus, LUZ-8F2-6B1 is a promising, safe, and effective agent for the prophylaxis and treatment of DENV infection.

01 Apr 2021·Bioorganic & Medicinal ChemistryQ3 · MEDICINE

Structural modifications on indole and pyrimidine rings of osimertinib lead to high selectivity towards L858R/T790M double mutant enzyme and potent antitumor activity

Q3 · MEDICINE

Article

Author: Liu, Qiao ; Chen, Chen ; Li, Zerui ; Fang, Lei ; Luo, Yanli

EGFR inhibitors represent a significant milestone for treatment of non-small cell lung cancer, however, they suffer from the acquired drug resistance. Utilizing osimertinib as the lead compound, this work has explored the structural modifications on the indole and pyrimidine rings of osimertinib to generate novel osimertinib derivatives. The in vitro enzymatic and cellular studies showed that the derivatives possessed high selectivity towards double mutant EGFR and potent antitumor activity. Particularly, compound 6b-1, the most active compound, exhibited excellent inhibitory activity against double mutant EGFR (IC₅₀ = 0.18 nM) and wild-type EGFR (IC₅₀ = 2.89 nM) as well as H1975 cells (IC₅₀ = 1.44 nM). Western blot analysis showed that 6b-1 completely inhibited double mutant EGFR and Erk phosphorylation. In vivo test using xenograft model indicated that compound 6b-1 had better antitumor efficacy than osimertinib. More importantly, 6b-1 displayed many advantages in the pharmacokinetic study, including better oral bioavailability and metabolism character.

100 Deals associated with Lerdelimumab

External Link

KEGG	Wiki	ATC	Drug Bank
-	Lerdelimumab	-	DB06557

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cataract	Phase 3	-	Cambridge Antibody Technology	-
Cataract	Phase 3	-	Genzyme Corp.	-
Cicatrix	Phase 3	-	Genzyme Corp.	-
Cicatrix	Phase 3	US	Cambridge Antibody Technology	-
Cicatrix	Phase 3	-	Cambridge Antibody Technology	-
Cicatrix	Phase 3	ZA	Cambridge Antibody Technology	-
Vitreoretinopathy, Proliferative	Phase 3	GB	Cambridge Antibody Technology	-
Vitreoretinopathy, Proliferative	Phase 3	-	Genzyme Corp.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ARVO2004	Phase 2	Cicatrix	56	Trabio	(natkriytuk) = Events coded to 'Eye Disorders' were the most common, comprising 84% of all events; and of these the most common were in the 'Ocular Infections, Irritations and Inflammations' category with 14% Trabio patients and 25% of the placebo patients reporting one or more events pqotqqejdm (wqgkxfoziq )	Positive	01 May 2004
				Placebo
CAT-152 (ARVO2003)	Not Applicable	TGFß2	-	CAT-152 (100µg)	(tbksgyoqre) = ouievladsa dmmeywrpqq (tumalbvubh ) View more	Positive	01 May 2003
				Placebo (phosphate buffered saline)	(qgnugeluqs) = wzezffizmi pmjztmelhy (tjbcwtjfjr )
ARVO2003	Not Applicable	Blister Maintenance	27	CAT-152	(jhpqujvtfz) = 5-FU caused corneal epitheliopathy (p=0.003) sbitmzmhny (mtncpzhshi )	-	01 May 2003
				5-FU
ARVO2002	Not Applicable	-	54	CAT-152 (1mg/ml)	(lktjrgvlvt) = xhyctkosws vdvtavtspl (eqxhquryrw )	-	01 Dec 2002
				5-fluorouracil (5-FU) (50mg/ml)	(lktjrgvlvt) = ypiorftnxi vdvtavtspl (eqxhquryrw )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Lerdelimumab

Overview

Basic Info

Gene Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation